{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T00:20:08Z","timestamp":1703982008552},"reference-count":12,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2023]]},"DOI":"10.3960\/jslrt.23033","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T22:17:01Z","timestamp":1701296221000},"page":"266-269","source":"Crossref","is-referenced-by-count":0,"title":["Significant response of patients with transformed follicular lymphoma                    with rapid disease progression to CAR-T therapy"],"prefix":"10.3960","volume":"63","author":[{"given":"Taichi","family":"Hirano","sequence":"first","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases,                            Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiro","family":"Tatetsu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases,                            Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikiko","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases,                            Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Shichijo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases,                            Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases,                            Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuho","family":"Tsujihashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases,                            Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Miyakawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kumamoto Shinto General Hospital,                            Kumamoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Kumamoto University                            Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases,                            Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Uchiba","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases,                            Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichirou","family":"Yasunaga","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases,                            Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kisato","family":"Nosaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases,                            Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rheumatology and Infectious Diseases,                            Kumamoto University Hospital, Kumamoto, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Goto                            H,                                Kitawaki                            T,                                Fujii                            N                    <i>et al.<\/i> Safety and efficacy of tisagenlecleucel in patients with                    relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan.                    Int J Clin Oncol. 2023; 28: 816-826.","DOI":"10.1007\/s10147-023-02334-w"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Gauthier                            J,                                Gazeau                            N,                                Hirayama                            AV                    <i>et al.<\/i> Impact of CD19 CAR T-cell product type on outcomes in                    relapsed or refractory aggressive B-NHL. Blood. 2022; 139:                    3722-3731.","DOI":"10.1182\/blood.2021014497"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Vercellino                            L, Di                                Blasi                            R,                                Kanoun                            S                    <i>et al.<\/i> Predictive factors of early progression after CAR T-cell                    therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;                    4: 5607-5615.","DOI":"10.1182\/bloodadvances.2020003001"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Wada                            F,                                Jo                            T,                                Arai                            Y                    <i>et al.<\/i> T-cell counts in peripheral blood at leukapheresis                    predict responses to subsequent CAR-T cell therapy. Sci Rep. 2022; 12:                    18696.","DOI":"10.1038\/s41598-022-23589-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Deng                            Q,                                Han                            G,                                Puebla-Osorio                            N                    <i>et al.<\/i> Characteristics of anti-CD19 CAR T cell infusion                    products associated with efficacy and toxicity in patients with large B cell                    lymphomas. Nat Med. 2020; 26: 1878-1887.","DOI":"10.1038\/s41591-020-1061-7"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Haradhvala                            NJ,                                Leick                            MB,                                Maurer                            K                    <i>et al.<\/i> Distinct cellular dynamics associated with response to                    CAR-T therapy for refractory B cell lymphoma. Nat Med. 2022; 28:                    1848-1859.","DOI":"10.1038\/s41591-022-01959-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Bachy                            E, Le                                Gouill                            S, Di                                Blasi                            R                    <i>et al.<\/i> A real-world comparison of tisagenlecleucel and                    axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B                    cell lymphoma. Nat Med. 2022; 28: 2145-2154.","DOI":"10.1038\/s41591-022-01969-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Nydegger                            A,                                Novak                            U,                                Kronig                            MN                    <i>et al.<\/i> Transformed lymphoma is associated with a favorable                    response to CAR-T-cell treatment in DLBCL patients. Cancers (Basel). 2021; 13:                    6073.","DOI":"10.3390\/cancers13236073"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Watanabe                            T. The Tumor                    Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with                    Therapeutic Potential. Int J Mol Sci. 2021; 22: 5352.","DOI":"10.3390\/ijms22105352"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Jacobson                            CA,                                Chavez                            JC,                                Sehgal                            AR                    <i>et al.<\/i> Axicabtagene ciloleucel in relapsed or refractory                    indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2                    trial. Lancet Oncol. 2022; 23: 91-103.","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Fowler                            NH,                                Dickinson                            M,                                Dreyling                            M                    <i>et al.<\/i> Tisagenlecleucel in adult relapsed or refractory                    follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022; 28:                    325-332.","DOI":"10.1038\/s41591-021-01622-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Freudenberg                            LS,                                Antoch                            G,                                Sch\u00fctt                            P                    <i>et al.<\/i> FDG-PET\/CT in re-staging of patients with lymphoma. Eur                    J Nucl Med Mol Imaging. 2004; 31: 325-329.","DOI":"10.1007\/s00259-003-1375-y"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/4\/63_23033\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T04:58:16Z","timestamp":1703912296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/63\/4\/63_23033\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.23033","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"23033"}}